Markers of acute myeloid leukemia stem cells
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsRavindra Majeti, Irving L. Weissman
Life of this patent
Estimating the term…
Abstract
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
Claims19
A method for characterizing an acute myeloid leukemia from a patient, the method comprising:
- contacting a patient sample with reagents specific for a differentially expressed marker or combination of markers set forth in Table 1;
- quantitating the number of marker expressing cancer cells,
- wherein the presence of marker expressing cancer cells is indicative of the presence of AML stem cells (AMLSC).
A method of screening a candidate chemotherapeutic agent for effectiveness against an AMLSC, the method comprising:
- contacting an AMLSC expressing a polypeptide set forth in Table 1 with a candidate agent, and
- determining the effectiveness of said agent against said AMLSC.
A method of targeting or depleting AML cancer stem cells, the method comprising contacting reagent blood cells with an agent that specifically binds a marker or combination of markers set forth in Table 1 in order to target or deplete AMLSC.
A method for the diagnosis or staging of AML, the method comprising:
- determining the upregulation of expression of a genetic sequence selected from those listed in Table 1.
Dependencies are inferred from the claim text.